Podcast Episode
The updated guidance affects all drugs in the class, including Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic, which have become household names in the global obesity treatment market.
To put this in context, approximately 25.4 million packs of these medications have been dispensed in the UK over the past five years, making severe reactions statistically rare but nonetheless significant for those affected.
Professor Matt Brown, Chief Scientific Officer at Genomics England, believes genetic testing could prevent around a third of adverse drug reactions. The research aims to enable more personalised prescribing in the future, potentially identifying high-risk patients before they begin treatment.
UK Issues Urgent Warning Over Fatal Pancreatitis Risk in Popular Weight Loss Drugs
January 30, 2026
Audio archived. Episodes older than 60 days are removed to save server storage. Story details remain below.
Britain's medicines regulator has strengthened warnings about rare but potentially fatal cases of severe pancreatitis linked to popular weight-loss medications including Wegovy, Ozempic, and Mounjaro, following reports of 19 deaths and over 1,200 adverse reactions.
UK Regulator Sounds Alarm on Weight Loss Drug Deaths
Britain's Medicines and Healthcare products Regulatory Agency has issued strengthened warnings about GLP-1 receptor agonist medications after receiving reports of deaths linked to severe pancreatitis in patients taking popular weight-loss drugs.The updated guidance affects all drugs in the class, including Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic, which have become household names in the global obesity treatment market.
The Numbers Behind the Warning
Between 2007 and October 2025, the MHRA received 1,296 Yellow Card reports of pancreatitis associated with GLP-1 medications. Of these, 19 resulted in fatalities and 24 involved necrotising pancreatitis, a particularly dangerous form where pancreatic tissue begins to die.To put this in context, approximately 25.4 million packs of these medications have been dispensed in the UK over the past five years, making severe reactions statistically rare but nonetheless significant for those affected.
Millions at Potential Risk
Research from University College London estimates that 1.6 million adults across England, Wales, and Scotland used GLP-1 medications for weight loss between early 2024 and early 2025. An additional 3.3 million people have expressed interest in starting the drugs, highlighting the massive scale of potential exposure.Genetic Research Could Transform Prescribing
The MHRA is working with Genomics England through the Yellow Card Biobank to investigate whether certain genetic profiles make some patients more susceptible to developing pancreatitis while taking these medications.Professor Matt Brown, Chief Scientific Officer at Genomics England, believes genetic testing could prevent around a third of adverse drug reactions. The research aims to enable more personalised prescribing in the future, potentially identifying high-risk patients before they begin treatment.
What Patients Should Watch For
The regulator has urged patients and healthcare providers to remain alert to symptoms of pancreatitis, including severe, persistent stomach pain that may radiate to the back, accompanied by nausea and vomiting. Patients who develop confirmed pancreatitis should not restart GLP-1 treatment.Published January 30, 2026 at 1:31am
